French drugmaker, Sanofi has appointed Paul Hudson to replace the current CEO, Olivier Brandicourt.
According to his profile on Bloomberg, Paul Hudson has been the Chief Executive Officer of Novartis Pharmaceuticals at Novartis AG since July 1, 2016. Mr. Hudson served as the President of Astrazeneca US and also served as an Executive Vice President of North America at AstraZeneca Pharmaceuticals LP until June 08, 2016.
He was responsible for leading AstraZeneca’s commercial operations in North America and represents the region as a Member of the Senior Executive Team. In this capacity, he is accountable for driving growth and maximizing contribution of North America to AstraZeneca’s global business. He served as an Executive Vice President of North America and President of AstraZeneca US at AstraZeneca PLC from January 2013 to June 8, 2016.
He served as the President of AstraZeneca’s business in Spain. He joined AstraZeneca in 2006 as Vice President and Primary Care Director, UK. He served as a Representative Director and President of AstraZeneca K. K., the Japanese subsidiary of AstraZeneca PLC. He worked for Schering Plough, where he held roles of increasing seniority, including leading biologics global marketing, based in the US. He began his career at GSK UK and Sanofi-Synthelabo UK with roles in sales and marketing.
He has served as a Standing Board Member of JPMA (Japan Pharmaceuticals Manufacturers Association) and EFPIA (European Federation of Pharmaceutical Industries and Associations) in Japan. He is Member of Healthcare Leadership Council and Member of the Value & Science Driven Health Care Roundtable at Institute of Medicine.
Mr. Hudson received a degree in Economics from Manchester Metropolitan University and a DipM from the UK’s Chartered Institute of Marketing.
Olivier Brandicourt is due to retire September, according to a statement by Sanofi.